Objective
The 2022 Monkeypox outbreak is unprecedented in scale and cases are still active in South America and starting to appear in South-East Asia. Many questions about Monkeypox virus disease remain unanswered to this day, particularly concerning the management of patients. MPX-RESPONSE aims to increase our knowledge of the monkeypox virus disease, to improve its therapeutic management and to further inform public health policies and guidelines through four Work Packages (WP). WP2 (MOSAIC) will assess clinical and virological outcomes of Monkeypox patients treated or not with antiviral drugs, focusing treatment on the most severe cases. WPs 3 and 4 will conduct randomized clinical trials (RCT) with the most promising antiviral therapy, tecovirimat, targeting patients in Europe (WP3-EPOXI) and globally in collaboration with WHO (WP4-UNITY); particularly in mild and moderate cases. A common primary outcome will be shared between the two RCTs and EPOXI will include additional objectives regarding pharmacological, immunological and virological outcomes in six to ten EU/EEA countries and fulfill in particular EMA requirements for treatment authorisation. A continuous systematic review and individual patient meta-analysis will summarize all randomized evidence of the interventions for monkeypox. Finally, the project will make sure that acquired knowledge is integrated into public health policies and guidelines and that adequate messages are shared with the general public and high-risk populations with the help of patients’ representatives and associations (WP1-COORDINATE). To accomplish these objectives, MPX-RESPONSE will build on the expertise and networks of multiples partners including Ecraid and EU-RESPONSE and will reinforce and broaden Europe’s capacity to respond rapidly to public health emergencies.
Fields of science
Keywords
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
75654 Paris
France
See on map
Participants (13)
0450 Oslo
See on map
37129 Verona
See on map
75015 PARIS
See on map
75012 Paris
See on map
28046 MADRID
See on map
3584 BA Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
3584 CX Utrecht
See on map
2000 Antwerpen
See on map
3015 GD Rotterdam
See on map
21040 900 Rio De Janeiro
See on map
0456 Oslo
See on map
75015 Paris
See on map
C1202ABB BUENOS AIRES
See on map
Partners (3)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
4051 Basel
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Participation ended
1205 Geneve 14
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1211 Geneve
See on map